cAMPfield Therapeutics raised a $180 million Series A to develop prifemilast, an oral PDE4B-selective therapy for inflammatory bowel disease. The company said the program is intended as an alternative to potent biologics such as Humira and Entyvio, targeting patients who do not achieve deep remission or who discontinue current therapies. Prifemilast traces back to vTv Therapeutics, which licensed the compound to Newsoara Biopharma for multiple Asian markets and later expanded rights. cAMPfield now holds rights outside of China and highlighted PDE4B selectivity—seeking efficacy while reducing dose-limiting adverse effects associated with PDE4D. cAMPfield’s leadership includes executives and veterans associated with prior IBD and GI development and commercialization, including experience tied to Entyvio, Otezla, Zeposia, and Humira. The company said early data in psoriasis showed robust efficacy with treatment discontinuation rates comparable to placebo. The round reinforces investor focus on oral small molecules for IBD, particularly mechanisms that can maintain anti-inflammatory potency without the tolerability challenges historically seen in PDE4 programs.